BPC-157 vs ARA-290 (Cibinetida)
BPC-157 is mainly studied for recovery, tissue repair, gut health. while ARA-290 (Cibinetida) is studied for recovery, comfort, inflammatory balance. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| BPC-157 | ARA-290 (Cibinetida) | |
|---|---|---|
| Category | Regenerative | Regenerative |
| Studied for | Recovery, tissue repair, gut health. | Recovery, comfort, inflammatory balance. |
| How it acts | A peptide associated with tissue-repair signaling; studied for its relationship with angiogenesis and recovery of soft tissue and the digestive tract. | A peptide studied for its relationship with tissue-repair pathways and modulation of discomfort associated with neural inflammation. |
| Evidence level | Limited human evidence | Human trials available |
How they differ
Although sometimes mentioned together, BPC-157 and ARA-290 (Cibinetida) do not target the same thing. BPC-157: A peptide associated with tissue-repair signaling; studied for its relationship with angiogenesis and recovery of soft tissue and the digestive tract. ARA-290 (Cibinetida): A peptide studied for its relationship with tissue-repair pathways and modulation of discomfort associated with neural inflammation.
See full entry: BPC-157 → · See full entry: ARA-290 (Cibinetida) →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between BPC-157 and ARA-290 (Cibinetida)?
BPC-157 targets recovery, tissue repair, gut health. and ARA-290 (Cibinetida) targets recovery, comfort, inflammatory balance. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, ARA-290 (Cibinetida) has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for BPC-157 vs ARA-290 (Cibinetida) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Reviewreview HSS J · 2025 · PMID 40756949 →
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healingreview Curr Rev Musculoskelet Med · 2025 · PMID 40789979 →
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performancereview Sports Med · 2026 · PMID 41966639 →
- Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?review Arthroscopy · 2025 · PMID 39265666 →
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber densityhuman Mol Med · 2013 · PMID 24136731 →
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabeteshuman Mol Med · 2015 · PMID 25387363 →
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Painhuman Invest Ophthalmol Vis Sci · 2017 · PMID 28475703 →
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edemahuman J Clin Med · 2020 · PMID 32674280 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.